These facts come from FDA’s list of registered outsourcing facilities, updated November 17, 2026, and from the inspection report FDA posted with it.1 None of the 164 FDA warning letters about GLP-1 drugs in our database names this company.
What does FDA’s record show, in brief?
| Facility | Nubratori, Inc. |
| Location | Torrance, California |
| Type | 503B outsourcing facility |
| Registered since | February 24, 2017 |
| Latest registration | November 5, 2026 |
| Last FDA inspection | December 11, 2025 |
| Inspection dates | 12/1/2025 to 12/11/2025 |
| Form 483 | Issued, 3 observations |
| FDA action after the inspection | Response Letter Issued 4/29/2026; Warning Letter Closeout Issued 7/27/2026; FMD-145 Issued 7/21/202 |
| Compounds sterile drugs from bulk | Yes |
| FDA warning letters on GLP-1 drugs | 0 |
What did FDA’s investigators observe?
The Form 483 from the inspection of 12/11/2025 lists 3 observations. We sorted them by what each one is about, from the words of its opening sentence; the full wording is in FDA’s document.2
| What the observation is about | Observations |
|---|---|
| Sterility and aseptic processing | 2 |
| Written procedures and quality unit | 1 |
FDA’s scan of the form is an image with a text layer; we do not quote it here because the text layer misreads some letters. Read the original on fda.gov.
Has this facility recalled any drugs?
FDA’s enforcement reports list 1 recalled product from this facility, from April 15, 2025 to April 15, 2025: 1 in Class II. None of them names a GLP-1 drug. Class I is the most serious: FDA uses it when the product could cause serious harm.3
| Started | Class | Product | Reason |
|---|---|---|---|
| 2025-04-15 | II | Dexonto 0.4% (dexamethasone sodium phosphate) solution 20 mg/5 mL (4 m | Labeling: Incorrect or Missing Lot and/or Expiration date: Individual vials of Dexonto 0.4%, are labeled correctly with … |
Is the pharmacy behind my prescription on FDA’s list?
Type a pharmacy name or city. The search runs over all 100 facilities on FDA’s list; a 503A pharmacy that compounds for individual prescriptions is licensed by its state and is not on this list.
Where are the registered outsourcing facilities?
8 of the 100 facilities on FDA’s list are in California. The chart counts them by state; choose a view to see which ones FDA has inspected.
Which other facilities are in the same state?
What does it mean that a pharmacy is a 503B outsourcing facility?
An outsourcing facility is a compounder that has chosen to register with FDA under section 503B of the Federal Food, Drug, and Cosmetic Act. It must re-register every year between October 1 and December 31 and pay an annual fee; a facility that does not is removed from FDA’s list on January 1.1 Once registered, it joins the list of facilities FDA plans to inspect on a risk-based schedule.1
A Form FDA 483 lists what investigators observed during an inspection. FDA states that a 483 is issued when investigators see significant objectionable conditions, and that it is not a final agency determination that the law was broken.1 Registration is not FDA approval of the drugs a facility makes: compounded drugs are not FDA-approved.
Sources
- FDA. Facilities registered as human drug compounding outsourcing facilities under section 503B, updated November 17, 2026, with its notes on registration and inspections. fda.gov
- FDA. Form FDA 483, inspection of Nubratori, Inc., 12/1/2025 to 12/11/2025. fda.gov
- FDA. Drug recall enforcement reports for Nubratori, Inc., read through openFDA on November 20, 2026. open.fda.gov
Log every dose in mg with the vial it came from, so there is a record if something goes wrong.
Open Dose Insider